Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vistusertib in Recurrent Grade II-III Meningioma
NCT03071874Phase 2Unknown
- Sponsor
- Massachusetts General Hospital
- Start
- Oct 2017
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vistusertib in meningioma, sponsored by Massachusetts General Hospital. Status: unknown.
02
Drugs
vistusertib
03
Conditions
meningioma
Beyond the preview
Go deeper on NCT03071874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03071874.